25 08, 2017 Deans ZC et al., Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey. Diatech Pharmacogenetics2017-10-02T14:18:53+02:00 Leggi di più
24 08, 2017 Annamaria Ruzzo et al., Dihydropyrimidine dehydrogenase pharmaco- genetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. British Journal of Cancer Diatech Pharmacogenetics2017-08-28T16:02:44+02:00 Leggi di più
10 08, 2017 Gianni Bussolati et al., Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. Plos One Diatech Pharmacogenetics2017-08-28T15:42:16+02:00 Leggi di più
19 07, 2017 Marco Lucarelli et al., A New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology. The Journal of Molecular Diagnostics Diatech Pharmacogenetics2017-09-04T10:19:00+02:00 Leggi di più
19 07, 2017 Francesca Galuppini et al., BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology Diatech Pharmacogenetics2017-08-23T11:01:38+02:00 Leggi di più
18 07, 2017 Federico Pessina et al., Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. Future Medicine Diatech Pharmacogenetics2017-08-03T11:05:28+02:00 Leggi di più
8 07, 2017 Chiara Pesenti et al. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status Diatech Pharmacogenetics2017-09-14T09:58:03+02:00 Leggi di più
28 06, 2017 Pierina Navarria et al., Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study Diatech Pharmacogenetics2017-11-21T16:09:45+01:00 Leggi di più
16 06, 2017 Fabiana Pani et al., Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. Oncology Letters Diatech Pharmacogenetics2017-08-24T15:02:16+02:00 Leggi di più
15 06, 2017 Sara Mariani et al., Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. British Journal of Cancer Diatech Pharmacogenetics2017-08-08T13:06:52+02:00 Leggi di più
